# 2026-16727: Cancer Tests Downgraded to Class II: FDA's Device Shuffle

2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-08-17, effective 2026-09-16; PRIA reads it as touching household money (as of 2026-08-24).

- Canonical: https://policyrisk.com/federal-register/2026-16727
- As of: 2026-08-24
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16727
- Title: Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53184
- Published: 2026-08-17
- Effective: 2026-09-16
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-08-24

## In one line

Cancer Tests Downgraded to Class II: FDA's Device Shuffle

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.

## Effects PRIA read

- Manufacturers: PMA → 510(k) Pathway: benefit, high. If you make in situ hybridization (ISH) tests indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), those devices are reclassified from class III to class II effective September 16, 2026. After that date, manufacturers may submit a 510(…
- Patients: Faster Access to ISH Tests: benefit, medium. You may get access to more oncology in situ hybridization (ISH) tests sooner because manufacturers can seek 510(k) clearance instead of PMA after September 16, 2026. FDA expects this reclassification will enable more manufacturers to develop and market these tests, increasing availability for clini…
- Existing PMA Devices Can Continue Marketing: mixed, medium. Oncology therapeutic ISH-based test systems that had prior PMA approval and were legally marketed before September 16, 2026 may continue to be marketed under their existing PMA. If a manufacturer makes a change that could significantly affect safety or effectiveness or a major change in intended us…
- Validation Rules: Surrogate Samples Allowed; Stability Removed: benefit, medium. FDA revised the special controls: FDA will consider surrogate samples that adequately represent intended-use specimen types and biomarkers to supplement clinical specimens for precision/reproducibility studies (as determined by FDA). FDA also removed the previously proposed special control that wou…
- 510(k) Premarket Notification Still Required: cost, medium. FDA did not exempt oncology therapeutic ISH-based test systems from 510(k) requirements under section 510(m); therefore, persons who intend to market these class II devices must submit a 510(k) and obtain FDA clearance before marketing. These tests are prescription in vitro diagnostic (IVD) devices…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16727 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/17/2026-16727/hematology-and-pathology-devices-reclassification-of-in-situ-hybridization-test-systems-for-use-with)
- [2026-16727 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-17/pdf/2026-16727.pdf)

## Related
- [Previous: 2026-16723, Walnuts Grown in California; Changes to Administrative Requirements](https://policyrisk.com/federal-register/2026-16723)
- [Next: 2026-16757, Safety Zone; Fox River, Green Bay, WI](https://policyrisk.com/federal-register/2026-16757)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16727 (as of 2026-08-24).
